Frost & Sullivan Independent Equity Research

Cellect Biotechnology Ltd.: Company’s clinical development on track; we expect positive interim results in the coming months. Target Price unchanged.

logo_cellect-biotech

Company: Cellect Biotechnology Ltd.        

Sector: Biotechnology

Report type: Quarterly Update

Published on: August 30th, 2017

Cellect research articles:

Close Menu
Font Resize